Top Penny Stocks To Watch In February 2025

As global markets navigate a complex landscape marked by fluctuating interest rates and AI competition fears, investors are keenly observing how these factors influence stock performance. Despite the challenges, opportunities still exist in niche areas like penny stocks, which can offer unique growth potential when backed by strong financials. Although the term 'penny stock' may seem outdated, it remains relevant as these smaller or newer companies often present underappreciated chances for growth at lower price points.

Top 10 Penny Stocks

Name	Share Price	Market Cap	Financial Health Rating
Bosideng International Holdings (SEHK:3998)	HK$3.90	HK$44.8B	★★★★★★
DXN Holdings Bhd (KLSE:DXN)	MYR0.545	MYR2.71B	★★★★★★
Datasonic Group Berhad (KLSE:DSONIC)	MYR0.40	MYR1.11B	★★★★★★
Hil Industries Berhad (KLSE:HIL)	MYR0.85	MYR282.15M	★★★★★★
Polar Capital Holdings (AIM:POLR)	£4.98	£481.5M	★★★★★★
MGB Berhad (KLSE:MGB)	MYR0.70	MYR414.16M	★★★★★★
Foresight Group Holdings (LSE:FSG)	£3.71	£431.2M	★★★★★★
Embark Early Education (ASX:EVO)	A$0.77	A$141.28M	★★★★☆☆
Lever Style (SEHK:1346)	HK$1.14	HK$723.66M	★★★★★★
Helios Underwriting (AIM:HUW)	£2.27	£159.81M	★★★★★☆

Click here to see the full list of 5,702 stocks from our Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (SEHK:1349)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. focuses on the research, development, manufacture, and sale of bio-pharmaceutical products in China and has a market cap of HK$6.69 billion.

Operations: The company generates revenue of CN¥691.62 million from its pharmaceuticals segment.

Market Cap: HK$6.69B

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. recently provided earnings guidance indicating a significant decline in net profit for 2024, primarily due to increased R&D expenses as several projects advance in clinical trials. The company is debt-free, which removes concerns about interest payments, but it has experienced negative earnings growth over the past year and five years. While its short-term assets comfortably cover both short and long-term liabilities, the board and management team are relatively inexperienced with an average tenure of 1.8 years. Despite these challenges, the company's strategic focus on R&D could potentially yield future opportunities.

• Unlock comprehensive insights into our analysis of Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd stock in this financial health report.
• Review our historical performance report to gain insights into Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's track record.

Crazy Sports Group (SEHK:82)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Crazy Sports Group Limited is an investment holding company that operates as a digital sports entertainment community in the People's Republic of China, with a market capitalization of HK$0.53 billion.

Operations: The company generates revenue primarily through its Digital Sports Entertainment Business, amounting to HK$425.61 million.

Market Cap: HK$529.56M

Crazy Sports Group Limited, with a market cap of HK$0.53 billion, is currently unprofitable but has made strides in reducing losses by 44.9% annually over the past five years. Despite an increased debt to equity ratio from 0.4% to 1.5%, the company maintains more cash than total debt and a positive free cash flow, providing a cash runway exceeding three years if growth continues at its current pace. However, short-term liabilities slightly exceed short-term assets by HK$19.2 million, indicating potential liquidity challenges despite long-term liabilities being well-covered by assets. The experienced management and board offer stability amid volatility concerns.

• Jump into the full analysis health report here for a deeper understanding of Crazy Sports Group.
• Gain insights into Crazy Sports Group's past trends and performance with our report on the company's historical track record.

Liaoning SG Automotive Group (SHSE:600303)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Liaoning SG Automotive Group Co., Ltd. manufactures and sells automobiles, axles, and other auto parts in China, with a market cap of CN¥1.98 billion.

Operations: No revenue segments have been reported for this company.

Market Cap: CN¥1.98B

Liaoning SG Automotive Group, with a market cap of CN¥1.98 billion, faces challenges as it remains unprofitable with increasing losses over the past five years. While its short-term assets of CN¥1.1 billion do not cover short-term liabilities of CN¥1.4 billion, long-term liabilities are adequately covered. The company's recent private placement aims to raise CN¥338.62 million through issuing shares at CNY 2.28 each, pending regulatory approvals and shareholder consent. Despite sufficient cash runway for over a year based on current free cash flow, its inexperienced board and management could impact strategic direction amid ongoing financial volatility.

• Click here and access our complete financial health analysis report to understand the dynamics of Liaoning SG Automotive Group.
• Examine Liaoning SG Automotive Group's past performance report to understand how it has performed in prior years.

Summing It All Up

• Investigate our full lineup of 5,702 Penny Stocks right here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com